The U.S. Food and Drug Administration has granted Orphan Drug Designation for Reolysin for the treatment of gastric cancer.  Reolysin is an investigational cancer therapeutics being developed by Oncolytics Biotech, a biotechnology company based in Calgary, Canada.  Gastric cancer is a rare form of cancer developing from the lining of the stomach and it is difficult to treat.  Although it is not a common cancer, it represents the third leading cause of cancer death worldwide. H. pylori infection is thought to be a major cause of gastric cancer.  Reolysin is a proprietary variant of the non-pathogenic reovirus found in the environment.  Research has shown that Reolysin can infect and selectively destroy cancer cells that harbor aberrant Ras pathway. Reolysin has been used alone and in combination with chemotherapy and radiotherapy for various cancers in multiple clinical trials.

 

References:

http://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Announces-Receipt-of-Orphan-Drug-Designation-from-the-US-FDA-for-Gastric-Cancer/default.aspx